Malignancy and IBD: Update on the Evidence

Malignancy and IBD: Update on the Evidence

Comprehensive Lecture Summary

1. Main Clinical Topics Discussed

• Epidemiology of malignancy in inflammatory bowel disease (IBD), encompassing both ulcerative colitis (UC) and Crohn's disease (CD)
• Colorectal cancer (CRC) risk, trends, and surveillance in IBD patients
• Non-colorectal malignancies associated with IBD (lymphoma, biliary cancers, skin cancers, small bowel cancers, lung cancer)
• Clinical decision-making regarding IBD management in patients with concurrent or prior malignancy
• Global burden of IBD and its implications for cancer risk management

2. Key Learning Points, Guidelines, and Recommendations

Colorectal Cancer Risk Factors in IBD:

• Extensive UC confers the highest CRC risk; colonic Crohn's disease also carries elevated risk
• PSC patients represent a high-risk subgroup requiring annual colonoscopy from time of diagnosis (not deferred 7–10 years as in standard protocols)
• Additional risk factors include: younger age of IBD diagnosis, male sex, greater disease extent and activity, family history of CRC
• Isolated proctitis does not confer increased CRC risk; most current surveillance protocols reflect this, though many clinicians continue to survey these patients in practice
• Pseudopolyps: controversial risk factor; primary concern is their potential to obscure true dysplastic lesions

Surveillance Recommendations:

• Colonoscopic surveillance with dye-spraying (chromoendoscopy) is the current standard
• Evidence supports surveillance as effective: higher cancer detection rates observed in non-surveilled vs. surveilled IBD patients
• Clinicians should individualize surveillance intensity based on whether patients resemble population-based cohorts or high-risk referral populations

Other Malignancies:

• Biliary cancers: primarily elevated in PSC patients
• Lymphoma risk: elevated in IBD; will be discussed in further detail in the lecture
• Small bowel cancer: increased in both CD and UC; difficult to diagnose pre-operatively; consider in patients with refractory small bowel stricturing disease
• Rectal cancer: notably not significantly increased in Crohn's disease, consistent with its rectal-sparing phenotype
• Lung cancer: increased in CD specifically

3. Specific Clinical Data, Statistics, and Study Results Cited

• Meta-analysis of population-based studies: Confirmed elevated risks of multiple malignancies in IBD (both UC and CD), independent of medication use
• CRC risk in UC: Approximately 2-fold increased risk broadly; one updated study reported hazard ratio of 1.7
• Declining CRC trends (Danish/Swedish cohorts):

- CRC hazard ratio decreased from 1.66 to 1.38 over time

- Parallel decrease in CRC-related mortality observed

- Swedish population-based data demonstrated decade-over-decade improvement in CRC death rates

• Global IBD burden (2017 publication, data from 2010): India identified as potentially carrying the greatest absolute burden of UC patients globally, underscoring the international relevance of these findings
• Surveillance efficacy data: Multiple large single-center studies (including Harvard/Brigham-affiliated research) demonstrated higher cancer detection rates among inadequately surveilled IBD patients compared to those in active surveillance programs

4. Practical Takeaways for Clinicians

• Remember the ~2-fold CRC risk in extensive UC as a practical benchmark for patient counseling and trainee education
• Do not apply standard surveillance intervals to PSC-IBD patients — these patients require annual colonoscopy from diagnosis, without the typical 7–10 year delay
• Isolated proctitis patients may not require the same intensive surveillance as extensive colitis; be aware of guideline nuances even if practice habits differ
• Declining CRC incidence and mortality in IBD is encouraging and likely reflects improved surveillance protocols and potentially improved disease control with modern therapies — the clinical question of whether better treatment reduces CRC risk remains an important and evolving area
• Small bowel malignancy, though rare, should remain on the differential for IBD patients — particularly those with Crohn's disease and refractory or stricturing small bowel disease unresponsive to therapy
• **IBD management